Clinical and baseline demographic data.

<p>Clinical and baseline demographic data.</p

Power to predict stability or change of long-term anti-JCV antibody status.

<p>Power to predict stability or change of long-term anti-JCV antibody status.</p

Spearman correlation between anti-JCV antibody index and patients’ age.

<p>The correlation between the rank of patient's age and the rank of anti-JVC antibody index is visualized, i.e. the Spearman correlation coefficient with its significance.</p

Trend analyses for each analyte for those individuals with two CSF samples.

<p>Both EX-RRMS and SPMS patients are grouped in the same graph.</p

Percentages of patients switching between different anti-JCV antibody index categories.

<p>(A) Percentage of patients with anti-JCV antibody index ≤0.9 at baseline (n = 66) switching to higher index categories at least once during follow-up. (B) Percentage of patients with positive anti-JCV serostatus and antibody index ≤0.9 at baseline (n = 23) switching to higher index categories at least once during follow-up. (C) Percentage of patients with anti-JCV antibody index >0.9 and ≤1.5 at baseline (n = 19) switching to higher or lower index categories at least once during follow-up. There was no patient remaining within the baseline index category during follow-up. (D) Percentage of patients with anti-JCV antibody index >1.5 at baseline (n = 69) switching to lower index categories at least once during follow-up.</p

Ratio of CSF to serum chemokine levels in normal patients as well as the relationship to molecular size.

<p>A). Ratio of the CSF to serum chemokine concentrations for normal controls. B). Relationship between the molecular weight of the analyte and the CSF/serum ratio (only normal subjects). Only CCL21 and CXCL12 are plotted and CXCL9, CXCL13 and CCL19 would roughly overlay these values. Chemokines were assumed to be dimeric, BAFF trimeric, IgG dimeric, IgA tetrameric and IgM pentameric. Values above the line are consistent with local CNS production. C). Corresponding Ig indices for the different cohorts. </p

Longitudinal change of anti-JCV serostatus.

<p>Frequency of conversion and reversion of anti-JCV serostatus from baseline throughout follow-up.</p

Evolution of anti-JCV antibody index.

<p>Anti-JCV antibody indices are displayed in seronegative and seropositive patients at the different time points during follow-up. At each visit, the total number of patients, the number of anti-JCV antibody positive patients and their distribution among different index categories are shown. JCV, John Cunningham virus.</p

Comparison of the levels of the inflammatory chemokines in serum and CSF.

<p>(A) Concentrations of CXCL9, CXCL10, and CCL2 and (B) the cytokine BAFF are plotted as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0081007#pone-0081007-g002" target="_blank">Figure 2</a>. </p

Comparison of the levels of the lymphoid chemokines CXCL12, CXCL13, CCL19 and CCL21 in serum and CSF.

<p>Chemokine concentrations are plotted with box and whiskers (10-90% range) overlaid on the scatter plots (each patient is a symbol). The CSF/serum ratio is presented on the right side. Data are shown for normal controls (NC), relapsing-remitting MS (RRMS), RRMS patients with acute exacerbations (EX-RRMS) and secondary progressive MS patients (SPMS). In those cases with EX-RRMS (9), SPMS (11) and RRMS (2) patients with second lumbar punctures, data from both samples are included. Statistical significance was assessed using only the baseline data and is indicated by asterisks at the bottom of each graph (ANOVA). Data at the lower limit of quantitation were excluded from the ratio plots. </p